Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

PMID:
29247021
2.

FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.

Erbe AK, Wang W, Goldberg J, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Mier JW, Panka DJ, McDermott DF, Sondel PM.

Clin Cancer Res. 2017 May 1;23(9):2159-2168. doi: 10.1158/1078-0432.CCR-16-1874. Epub 2016 Oct 14.

3.

Novel drugs that target the metabolic reprogramming in renal cell cancer.

van der Mijn JC, Panka DJ, Geissler AK, Verheul HM, Mier JW.

Cancer Metab. 2016 Jul 13;4:14. doi: 10.1186/s40170-016-0154-8. eCollection 2016. Review.

4.

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.

Wang X, Solban N, Khanna P, Callea M, Song J, Alsop DC, Pearsall RS, Atkins MB, Mier JW, Signoretti S, Alimzhanov M, Kumar R, Bhasin MK, Bhatt RS.

Oncotarget. 2016 Jul 5;7(27):41857-41869. doi: 10.18632/oncotarget.9621.

5.

Sunitinib activates Axl signaling in renal cell cancer.

van der Mijn JC, Broxterman HJ, Knol JC, Piersma SR, De Haas RR, Dekker H, Pham TV, Van Beusechem VW, Halmos B, Mier JW, Jiménez CR, Verheul HM.

Int J Cancer. 2016 Jun 15;138(12):3002-10. doi: 10.1002/ijc.30022. Epub 2016 Mar 1.

6.

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.

Sullivan RJ, Ibrahim N, Lawrence DP, Aldridge J, Giobbie-Hurder A, Hodi FS, Flaherty KT, Conley C, Mier JW, Atkins MB, McDermott DF.

Oncologist. 2015 Jun;20(6):617-8. doi: 10.1634/theoncologist.2015-0105. Epub 2015 May 18.

7.

Immune checkpoint inhibitors in the treatment of metastatic melanoma.

Mier JW.

Clin Ther. 2015 Apr 1;37(4):753-4. doi: 10.1016/j.clinthera.2015.02.002. Epub 2015 Feb 26. No abstract available.

PMID:
25726456
8.

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.

Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS.

Clin Cancer Res. 2015 Apr 15;21(8):1925-1934. doi: 10.1158/1078-0432.CCR-14-2031. Epub 2015 Jan 14.

9.

Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.

van der Mijn JC, Mier JW, Broxterman HJ, Verheul HM.

Drug Resist Updat. 2014 Oct-Dec;17(4-6):77-88. doi: 10.1016/j.drup.2014.10.003. Epub 2014 Oct 7. Review.

PMID:
25457974
10.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

11.

Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.

Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ.

Mol Cancer Ther. 2014 Dec;13(12):3210-8. doi: 10.1158/1535-7163.MCT-14-0349. Epub 2014 Oct 15.

12.

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ.

PLoS One. 2014 Jul 1;9(7):e101286. doi: 10.1371/journal.pone.0101286. eCollection 2014.

13.

The role of angiopoietins as potential therapeutic targets in renal cell carcinoma.

Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, Alsop DC, Mier JW, Atkins MB, Coxon A, Oliner J, Bhatt RS.

Transl Oncol. 2014 Apr;7(2):188-95. doi: 10.1016/j.tranon.2014.02.003. Epub 2014 Mar 4.

14.

Assaying for BRAF V600E in tissue and blood in melanoma.

Panka DJ, Mier JW, Sullivan RJ.

Methods Mol Biol. 2014;1102:117-36. doi: 10.1007/978-1-62703-727-3_8.

PMID:
24258977
15.
16.

PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells.

Zhu S, Cohen MB, Bjorge JD, Mier JW, Cho DC.

J Cell Mol Med. 2013 Mar;17(3):377-85. doi: 10.1111/jcmm.12019. Epub 2013 Feb 7. Erratum in: J Cell Mol Med. 2014 Jul;18(7):1490.

17.

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.

Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS.

Br J Cancer. 2013 Feb 5;108(2):319-26. doi: 10.1038/bjc.2012.591. Epub 2013 Jan 15.

18.

Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma.

Cho DC, Mier JW.

Curr Cancer Drug Targets. 2013 Feb;13(2):126-42. Review.

PMID:
23259857
19.

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.

Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhatt RS.

J Transl Med. 2011 Dec 21;9:220. doi: 10.1186/1479-5876-9-220.

20.
21.

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.

Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS.

PLoS One. 2011 Apr 29;6(4):e19144. doi: 10.1371/journal.pone.0019144.

22.

Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.

Pandya SS, Mier JW, McDermott DF, Cho DC.

BJU Int. 2011 Oct;108(8 Pt 2):E245-9. doi: 10.1111/j.1464-410X.2011.10096.x. Epub 2011 Feb 14.

23.

Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.

Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW.

Mol Cancer Ther. 2010 Oct;9(10):2793-802. doi: 10.1158/1535-7163.MCT-10-0477. Epub 2010 Aug 10.

24.

An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood.

Panka DJ, Sullivan RJ, Mier JW.

Melanoma Res. 2010 Oct;20(5):401-7. doi: 10.1097/CMR.0b013e32833d8d48.

25.

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.

Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW.

Clin Cancer Res. 2010 Jul 15;16(14):3628-38. doi: 10.1158/1078-0432.CCR-09-3022. Epub 2010 Jul 6.

26.

Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.

Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG Jr, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L.

Cancer. 2009 May 15;115(10 Suppl):2247-51. doi: 10.1002/cncr.24229.

27.

Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.

Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF.

J Immunother. 2009 Feb-Mar;32(2):181-5. doi: 10.1097/CJI.0b013e3181952b1d.

PMID:
19238017
28.

GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines.

Panka DJ, Cho DC, Atkins MB, Mier JW.

J Biol Chem. 2008 Jan 11;283(2):726-32. Epub 2007 Nov 8.

29.

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.

Cho D, Signoretti S, Regan M, Mier JW, Atkins MB.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s. Review.

30.

Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.

Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, Jewell RC, Bell WN, Thurmond LM, Weisenbach J, Roberts S, Dar MM.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4265-73.

31.

Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.

Panka DJ, Atkins MB, Mier JW.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2371s-2375s. Review.

32.

Innovations and challenges in melanoma: summary statement from the first Cambridge conference.

Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2291s-2296s.

33.

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.

Panka DJ, Wang W, Atkins MB, Mier JW.

Cancer Res. 2006 Feb 1;66(3):1611-9.

34.

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB.

J Clin Oncol. 2005 Jan 1;23(1):133-41. Erratum in: J Clin Oncol. 2005 Apr 20;23(12):2877.

PMID:
15625368
35.

Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells.

Panka DJ, Mier JW.

J Biol Chem. 2003 Sep 26;278(39):37632-6. Epub 2003 Jul 22.

36.

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.

Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB.

J Clin Oncol. 2003 Jul 1;21(13):2564-73.

PMID:
12829677
37.

Biological drug duo delivers one-two tumor punch.

Sosman JA, Mier JW.

Nat Med. 2003 Jun;9(6):649-50. No abstract available.

PMID:
12778160
38.
39.

Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF.

Mier JW.

J Immunother. 2003 Mar-Apr;26(2):95-6. No abstract available.

PMID:
12616100
40.
41.

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.

Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW.

Clin Cancer Res. 2002 Oct;8(10):3075-81.

42.
43.

Clinical use of systemic IL-12 therapy.

Gollob JA, Mier JW, Atkins MB.

Cancer Chemother Biol Response Modif. 2001;19:353-69. Review. No abstract available.

PMID:
11686023
44.

Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis.

Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H.

Blood. 2001 Nov 1;98(9):2720-5.

45.

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12.

Gollob JA, Veenstra KG, Mier JW, Atkins MB.

J Immunother. 2001 Jan-Feb;24(1):91-8.

PMID:
11211153
46.

Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells.

Panka DJ, Mano T, Suhara T, Walsh K, Mier JW.

J Biol Chem. 2001 Mar 9;276(10):6893-6. Epub 2001 Jan 5.

47.

Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections.

Gollob JA, Veenstra KG, Jyonouchi H, Kelly AM, Ferrieri P, Panka DJ, Altare F, Fieschi C, Casanova JL, Frank DA, Mier JW.

J Immunol. 2000 Oct 1;165(7):4120-6.

48.

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.

Clin Cancer Res. 2000 Jun;6(6):2201-8.

49.
50.

Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth.

Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R.

J Biol Chem. 2000 Jan 14;275(2):1209-15.

Supplemental Content

Support Center